Finasteride May Be Effective for Female Pattern Baldness.

News Writer: Laurie Barclay, MD CME Writer: Désirée Lie, MD, MSEd Disclosures Dismissal Date: District 21, 2006 ;  Valid for approval through MArch 21, 2007
Master’s degree 21, 2006 — propecia may be effective for the communication of female person radiation pattern hair loss (FPHL), according to the results of a piece reported in the Procession supply of Archives of Dermatology .
“If left untreated, FPHL may be rapidly grownup,” write Matilde Iorizzo, MD, from the Educational institution of Metropolis in Italy, and colleagues. “Treatment for FPHL consists mainly of topical minoxidil, which is effective but sometimes is not well accepted by the patient role.
The efficacy of oral antiandrogens is not well established.”
The great unwashed outpatient audience for hair disorders, 37 women with FPHL were treated with 2.5 mg/day of oral finasteride while taking an oral contraceptive containing drospirenone and ethinyl estradiol.
Efficacy outcomes included internal representation on global occupation, hair compactness resentment on videodermoscopy, and a self-administered questionnaire in which patients evaluated the results of discourse.
At 12-month follow-up, global business revealed that 23 (62%) of the 37 patients were improved, including 12 who were slightly improved, 8 who were moderately improved, and 3 who were greatly improved.
Of the remaining 14 patients, 13 had no betterment, and 1 semantic role was worse.
Twelve patients had a significant alteration in hair spacing set ( P = .002).
No patients had adverse reactions to the drug.
“Sixty-two percent of the patients demonstrated some shift of their hair loss with the use of finasteride, 2.5 mg/d, while taking the oral contraceptive,” the authors write. “It is unclear whether the someone was due to a higher medicine of finasteride (2.5 mg instead of 1 mg) or to its affiliation with the oral contraceptive containing drospirenone, which has an antiandrogenic meaning.
Further studies are necessary to understand which patterns of FPHL respond superior to this attention.”
Examination limitations include lack of randomization, blinding, medicine economic policy, and scalp biopsies.
“Further studies are needed to establish the optimal medicinal drug and mode of disposal of finasteride in premenopausal women and to definitively assess the efficacy of this drug compared with oral antiandrogens,” the authors conclude.
The authors have disclosed no relevant financial relationships.
Arch Dermatol.According to the authors, FPHL affects up to 50% of women during their life, can be a origin of plethora and social psychological state, and if untreated, may rapidly onward motion.
Tierce different patterns of FPHL have been identified: Public holiday tree, Ludwig, and the INSTANCE OFLady example.
Topical minoxidil is currently an approved tending but may not be well accepted by women.
Finasteride is a 5α-reductase type II inhibitor currently approved for male androgenetic alopecia at a medicine of 1 mg/day but is contraindicated in women of childbearing possibility because of teratogenic effects.
According to the authors, studies of finasteride at 1 mg/day have shown little outcome on hair maturation patterns for women with FPHL, and a higher dose may be needed for women.
The flow proceedings is an open descriptive room of a higher dose of finasteride (2.5 mg daily) combined with oral contraceptives to examine its burden on FPHL.
This is a part of article Finasteride May Be Effective for Female Pattern Baldness. Taken from "Propecia Finasteride 1mg" Information Blog